Found: 32
Select item for more details and to access through your institution.
Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study.
- Published in:
- Cancers, 2023, v. 15, n. 10, p. 2859, doi. 10.3390/cancers15102859
- By:
- Publication type:
- Article
Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO)
- Published in:
- Cancers, 2022, v. 14, n. 6, p. 1544, doi. 10.3390/cancers14061544
- By:
- Publication type:
- Article
Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34 + Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia.
- Published in:
- Cancers, 2021, v. 13, n. 2, p. 186, doi. 10.3390/cancers13020186
- By:
- Publication type:
- Article
An implementation study of electronic assessment of patient-reported outcomes in inpatient radiation oncology.
- Published in:
- Journal of Patient-Reported Outcomes, 2022, v. 6, n. 1, p. 1, doi. 10.1186/s41687-022-00478-3
- By:
- Publication type:
- Article
Spontaneous Remission of Acute Myeloid Leukemia Relapse after Hematopoietic Cell Transplantation in a High-Risk Patient with 11q23/MLL Abnormality.
- Published in:
- Acta Haematologica, 2008, v. 119, n. 2, p. 111, doi. 10.1159/000121827
- By:
- Publication type:
- Article
Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41408-022-00615-7
- By:
- Publication type:
- Article
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 5, p. 888, doi. 10.1111/bjh.16462
- By:
- Publication type:
- Article
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes ( MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 5, p. 917, doi. 10.1111/bjh.14345
- By:
- Publication type:
- Article
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy.
- Published in:
- British Journal of Haematology, 2013, v. 162, n. 2, p. 229, doi. 10.1111/bjh.12375
- By:
- Publication type:
- Article
FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
- Published in:
- Annals of Hematology, 2024, v. 103, n. 8, p. 2775, doi. 10.1007/s00277-024-05867-w
- By:
- Publication type:
- Article
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 7, p. 2299, doi. 10.1007/s00277-024-05665-4
- By:
- Publication type:
- Article
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 10, p. 2741, doi. 10.1007/s00277-023-05394-0
- By:
- Publication type:
- Article
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 3, p. 547, doi. 10.1007/s00277-023-05087-8
- By:
- Publication type:
- Article
Aggressive systemic mastocytosis: a diagnostic challenge in a patient with myotonic dystrophy type 2: a case report.
- Published in:
- 2019
- By:
- Publication type:
- case study
Managing patients with myelofibrosis and low platelet counts.
- Published in:
- 2017
- By:
- Publication type:
- journal article
JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib.
- Published in:
- 2015
- By:
- Publication type:
- case study
Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia.
- Published in:
- 2015
- By:
- Publication type:
- case study
Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.
- Published in:
- EJHaem, 2022, v. 3, n. 4, p. 1346, doi. 10.1002/jha2.591
- By:
- Publication type:
- Article
Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia.
- Published in:
- OncoTargets & Therapy, 2013, v. 6, p. 741, doi. 10.2147/OTT.S45459
- By:
- Publication type:
- Article
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 558, doi. 10.1002/hon.2898
- By:
- Publication type:
- Article
Clinical Discernment, Bone Marrow, and Molecular Diagnostics Are Equally Important to Solve the Phenotypic Mimicry among Subtypes of Myeloproliferative Neoplasms.
- Published in:
- Reports (MDPI AG), 2021, v. 4, n. 3, p. 1, doi. 10.3390/reports4030027
- By:
- Publication type:
- Article
Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97).
- Published in:
- Cancer Medicine, 2023, v. 12, n. 17, p. 18235, doi. 10.1002/cam4.6413
- By:
- Publication type:
- Article
Association of immune evasion in myeloid sarcomas with disease manifestation and patients' survival.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1396187
- By:
- Publication type:
- Article
Highly Elevated Serum Hepcidin in Patients with Acute Myeloid Leukemia prior to and after Allogeneic Hematopoietic Cell Transplantation: Does This Protect from Excessive Parenchymal Iron Loading?
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Highly Elevated SerumHepcidin in Patients with AcuteMyeloid Leukemia prior to and after Allogeneic Hematopoietic Cell Transplantation: Does This Protect fromExcessive Parenchymal Iron Loading?
- Published in:
- Advances in Hematology, 2011, v. 2011, p. 1, doi. 10.1155/2011/491058
- By:
- Publication type:
- Article
Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F‐ and MPLW515 L‐positive myelofibrosis.
- Published in:
- Genes, Chromosomes & Cancer, 2019, v. 58, n. 11, p. 747, doi. 10.1002/gcc.22781
- By:
- Publication type:
- Article
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2016, v. 142, n. 1, p. 317, doi. 10.1007/s00432-015-2050-y
- By:
- Publication type:
- Article
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
- Published in:
- Experimental Hematology & Oncology, 2015, v. 4, n. 1, p. 1, doi. 10.1186/s40164-015-0021-2
- By:
- Publication type:
- Article
Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) (MOMENTUM).
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 388
- By:
- Publication type:
- Article
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 377
- By:
- Publication type:
- Article
Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 19, p. 7140, doi. 10.3390/ijms21197140
- By:
- Publication type:
- Article